Today, Dr. Parkash Gill announced that Veglin is not released yet to restart it’s Phase 2 Clinical Trials, and the project continues to wait for FDA approval. Dr. Gill is working hard to restart Veglin within Phase 2 and is also working diligently to get EPH-B4 into Phase I Clinical Trials.
Please use our FaceBook link to obtain your FREE copy of our eBook that teaches you 10 easy steps on how to find and choose a clinical trial for Mesothelioma and how to prepare for it!
Ask Dr. Gill about your specific mesothelioma issues here: Ask Dr. Gill
Learn more about Veglin at this cancer research link: read more…
In addition to the eBook found at our Facebook fan page, also learn more about clinical trials from these links:
Today, Dr. Parkash Gill announced that Veglin is again being released for continued Phase 2 Clinical Trials by FDA approval. According to Gill, the studies for Veglin should be open within the month. He has completed and turned in the protocol and detail as required which will allow Phase 2 clinical studies to soon start up again on Veglin. Also, a Phase 1 clinical study on Eph B4, Dr. Gills other molecule, should be available soon.
Ask Dr. Gill about the upcoming study of Veglin, Phase 2 clinical trials… Click Here
Learn about Veglin at this MesoRFA link: read more…
And learn about participating in a clinical trial at these MesoRFA links:
Dr. Parkash Gill has invented Veglin, a type of antisense oligonucleotide anti-angiogenesis drug. Veglin has been under clinical trials phases I and II at the University of Southern California. This drug has demonstrated preliminary success with results of lowering VEGF levels in tumors. Tumor growth is aided by the protein VEGF. The results of the Phase I clinical trials using Veglin were released by Dr. Parkash Gill during the 40th Annual Meeting of the American Society of Clinical Oncology. The doctor said that results in some cases had shown Veglin to be capable of reduction of tumors and periodic stabilization.
Dr. Parkash Gill and Veglin wait for further FDA approval
PRESS RELEASE
April 30, 2011
Dr. Parkash Gill has announced that Veglin is not available until receiving FDA approval. This delay is considered normal and a required process by the FDA. Once the FDA approves, Alimta Cisplatin chemotherapy along with Veglin (a non-chemotherapy) will be the next protocol used.
to obtain your FREE copy of our eBook that teaches you 10 easy steps on how to find and choose a clinical trial for Mesothelioma and how to prepare for it!
